Abstracts tagged "COX inhibitors"

Abstract Number: L08 • ACR Convergence 2024
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging and Parallel-group Study to Evaluate the Safety and Efficacy of XG005 in Subjects with Painful Osteoarthritis of the Knee
Limin Ren¹, Wenjie Zheng², Zhenpeng Guan³, Yang Zhang⁴, Zeyu Huang⁵, Tong Li⁶, Yuwei Peng⁷, Qiuli Wu⁸, Wei Gou⁹, Wei Zhao¹⁰, Pengyan Qiao¹¹, Xiaoli Pan¹² and Guang-Liang Jiang¹³, ¹Peking University, People’s Hospital, Rheumatology and Immunology Department, Beijing, China, ²Yantai Yuhuangding Hospital of Qingdao University, Department of Orthopedics, Yantai, China, ³Peking University, Shougang Hospital, Department of Orthopedics, Beijing, China, ⁴Division of Orthopaedic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, ⁵West China Hospital of Sichuan University, Department of Orthopedics, Chengdu, China, ⁶Xiangya Hospital of Central South University, Rheumatology and Immunology Department, Changsha, China, ⁷PingXiang People’s Hospital, Rheumatology and Immunology Department, Pingxiang, China, ⁸Tianjin Medical University General Hospital, Department of Orthopedics, Tianjin, China, ⁹Hebei Petrochina Central Hospital, Rheumatology and Immunology Department, Langfang, China, ¹⁰Central Hospital Affiliated to Shenyang Medical College, Department of Orthopedics, Shenyang, China, ¹¹Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Rheumatology and Immunology Department, Taiyuan, China, ¹²Affiliated Hospital of Zunyi Medical University, Rheumatology and Immunology Department, Zunyi, China, ¹³Xgene Pharmaceutical, Lexington, MA
Background/Purpose: Osteoarthritis (OA) affects 595 million people globally; cases are projected to increase 49-95% for various joints by 2050 as populations age (GBD 2023). OA…
Abstract Number: 1476 • ACR Convergence 2024
Individualizing NSAIDs in Axial Spondyloarthritis Through a Series of N-of-1 Clinical Trials with Bayesian Analysis
Mark Hwang¹, Seokhun Kim², Shervin Assassi³, Joyce Samuel⁴, Charles Green², Jon Tyson⁴ and John Reveille⁵, ¹Department of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine, UTHealth Houston, Houston, TX, ²UTHealth Houston, Houston, ³UTHealth Houston Division of Rheumatology, Houston, TX, ⁴UTHealth Houston, Houston, TX, ⁵UTHealth Houston Division of Rheumatology, Houston
Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are first line pharmacological treatment for Axial Spondyloarthritis (axSpA), yet individual responses to different NSAIDs vary significantly. This study aims…
Abstract Number: 0546 • ACR Convergence 2022
COmparison of the Effect of Treatment with NSAIDs Added to Anti-TNF Therapy versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine over Two Years in Patients with Ankylosing Spondylitis (CONSUL): An Open-Label, Randomized Controlled, Multicenter Trial
Fabian Proft¹, Bukrhard Muche², valeria Rios-Rodriguez³, Murat Torgutalp⁴, Mikhail Protopopov⁵, Joachim Listing⁶, Maryna Verba⁷, Jan Brandt-Juergens⁸, Uta Kiltz⁹, Maren Sieburg¹⁰, Swen Jacki¹¹, Joachim Sieper⁴ and Denis Poddubnyy¹, ¹Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Charité University Hospital, CCM, Berlin, Germany, ³Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité - Universitätsmedizin, Berlin, Berlin, Germany, ⁵Charité Universitätsmedizin Berlin, Berlin, Germany, ⁶German Rheumatism Research Centre, Epidemiology Unit, Berlin, Germany, ⁷Charité – Universitätsmedizin Berlin, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ⁸Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁹Rheumazentrum Ruhrgebiet, Herne, Germany, ¹⁰Rheumatologische Facharztpraxis, Magdeburg, Germany, ¹¹Rheumatologische Schwerpunktpraxis, Tübingen, Germany
Background/Purpose: There is some evidence that NSAIDs, in particular celecoxib (CEL), might possess not only symptomatic efficacy but also disease-modifying properties in ankylosing spondylitis (AS),…
Abstract Number: 1751 • ACR Convergence 2022
Diagnosing the Cardiovascular Risk of VIOXX: A Place for Rofecoxib in Pain Management
Judith Boice, Mark Corrigan and Bradford Sippy, Tremeau Pharmaceuticals, Inc, Concord, MA
Background/Purpose: Traditional NSAIDs (tNSAIDs) are effective in treating arthritis pain but can be limited by GI adverse events and general bleeding related to platelet inhibition.…
Abstract Number: 1831 • ACR Convergence 2022
Establishing a Scientific Bridge to Historic VIOXX to Enable a Reintroduction of Rofecoxib: Pharmacokinetic Evaluation of TRM‑201 (Rofecoxib)
Judith Boice¹, Travis Helm¹, Maria Bermudez², Mark Corrigan¹ and Bradford Sippy¹, ¹Tremeau Pharmaceuticals, Inc, Concord, MA, ²Clinical Pharmacology of Miami, LLC, Miami, FL
Background/Purpose: TRM-201 (rofecoxib) is a cyclooxygenase-2 (COX-2) selective inhibitor being developed for the treatment of hemophilic arthropathy (HA) and acute migraine. Previously marketed as VIOXX,…
Abstract Number: 0732 • ACR Convergence 2021
Topical Rofecoxib for OA of the Knee
Bruce Register¹, Nancy Lane², Lee Simon³, John Newsam⁴, Edward Kisak⁴, Jed Pheneger⁵, John Galvin⁵, Jeffrey Klein⁶ and Marc Hochberg⁷, ¹BriOri BioTech, Inc., Newport Beach, CA, ²University of California Davis, Hillsborough, CA, ³SDG LLC, West Newton, MA, ⁴Tioga Research, Inc, San Diego, CA, ⁵Inotiv, Boulder, CO, ⁶Sinclair Research Center, Auxvasse, MO, Canada, ⁷University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Osteoarthritis remains a highly prevalent disease in the elderly, and there are currently no approved treatments that can modify the disease course. Currently, both…
Abstract Number: 1361 • 2018 ACR/ARHP Annual Meeting
Predictive Modeling of Therapeutic Response in Knee Osteoarthritis
Valentina Calamia¹, Florencia Picchi¹, Ignacio Rego-Pérez², Maria Camacho¹, Lucia González¹, Patricia Fernández³, Marta Herrero⁴, Helena Martinez⁴, Josep Vergés⁵, Cristina Ruiz-Romero⁶ and Francisco J Blanco⁷, ¹Rheumatology Research Group, Proteomics Unit-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain, ²Rheumatology Research Group, Genomic Unit, INIBIC-CHUAC, A Coruña, Spain, ³Proteomics group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, La Coruña, Spain, ⁴Clinical R&D Area, Bioiberica, SAU, Barcelona, Spain, ⁵Osteoarthritis Foundation International, Barcelona, Spain, ⁶Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ⁷Rheumatology Divison, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain
Background/Purpose: Phenotype identification in knee osteoarthritis (KOA) population could be useful for predicting drug response, allowing personalized interventions. In order to optimize therapeutic outcome in…
Abstract Number: 1434 • 2017 ACR/ARHP Annual Meeting
COX-2 Inhibitor Contributes Cell Death in Rheumatoid Arthritis Fibroblast-like Synoviocytes Via PI3K/AKT/mTOR Signaling Pathway Triggered By Autophagy
Sang-Hyon Kim¹, Jihye Bang², Ji-Min Kim¹, Chang-Nam Son¹, Jin-Nyeong Chae¹ and Hye-Jin Jeong³, ¹Division of Rheumatology, Department of Internal Medicine, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Republic of Korea, Daegu, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea, Republic of (South), ³Department of Rheumatology, Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of (South)
Background/Purpose: Recently, the possibilities that autophagy regulates apoptosis resistance and hyperplasia of fibroblast-like synoviocytes (FLS) were also presented. The aim of this study is to…
Abstract Number: 1647 • 2015 ACR/ARHP Annual Meeting
A Randomized, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of Etoricoxib in Patients with Rheumatoid Arthritis
Kara Bickham¹, Désirée van der Heijde², Narinder Rawal³, Joachim Sieper⁴, Boyd Scott⁵, Nancy Frontera¹, Sandhya Shah¹, Paul Stryszak¹, Dimitris Papanicolaou¹, Zoran Popmihajlov¹ and Paul Peloso¹, ¹Merck & Co., Inc., Kenilworth, NJ, ²University Hospital, Maastricht, Netherlands, ³Orebro University Hospital, Orebro, Sweden, ⁴Rheumatology, Charite - Campus Benjamin Franklin, Berlin, Germany, ⁵Merck Sharp & Dohme Corp., Whitehouse Station, NJ
Background/Purpose: Etoricoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, provides symptom modification in RA patients. Previous dose-ranging studies in RA demonstrated the clinical efficacy of etoricoxib 90…
Abstract Number: 2845 • 2015 ACR/ARHP Annual Meeting
A Randomized, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of Etoricoxib in Patients with Ankylosing Spondylitis
Eva Balazcs¹, Désirée van der Heijde², Narinder Rawal³, Joachim Sieper⁴, Boyd Scott⁵, Kara Bickham⁶, Nancy Frontera⁶, Paul Stryszak⁶, Dimitris Papanicolaou⁶, Zoran Popmihajlov⁶ and Paul Peloso⁶, ¹Department of Neuromusculoskeletal Rehabilitation, Sima F, Szentes, Hungary, ²University Hospital, Maastricht, Netherlands, ³Orebro University Hospital, Orebro, Sweden, ⁴University Clinic Benjamin Franklin, Berlin, Germany, ⁵Merck Sharp & Dohme Corp., Whitehouse Station, NJ, ⁶Merck & Co., Inc., Kenilworth, NJ
Background/Purpose: Etoricoxib 90 mg, a selective COX-2 inhibitor, provides symptom relief in ankylosing spondylitis (AS) patients. A prior study established etoricoxib 90 mg as safe…
Abstract Number: 1141 • 2012 ACR/ARHP Annual Meeting
Safety of Celecoxib and Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Juvenile Idiopathic Arthritis
Rachel E. Sobel¹, D. J. Lovell², Hermine Brunner³, Jennifer E. Weiss⁴, Paula W. Morris⁵, Beth S. Gottlieb⁶, Elizabeth C. Chalom⁷, Lawrence K. Jung⁸, Karen Onel⁹, Lisa Petinoit¹⁰, Donald P. Goldsmith¹¹, Staci Abramsky-Risman¹², James P., Young¹³ and Edward H. Giannini¹⁴, ¹Epidemiology, Worldwide Safety Strategy, Pfizer, Inc., New York, NY, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Pediatric Rheumatology, Hackensack Univ Med Ctr, Hackensack, NJ, ⁵Pediatrics, Univ of Arkansas for Med Sci, Little Rock, AR, ⁶Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ⁷Pediatrics, St. Barnabas Medical Center, Livingston, NJ, ⁸Pediatric Rheumatology, Children's National Medical Center, Washington, DC, ⁹Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ¹⁰Pediatric Rheumatology, 'Specially for Children, Dell Children's Medical Center, Austin, TX, ¹¹Pediatric Rheumaology, St Christopher's Hospital for Children/ Drexel College of Medicine, Philadelphia, PA, ¹²Pfizer Inc, New York, NY, ¹³United BioSource Corporation, Ann Arbor, MI, ¹⁴Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Celecoxib, a selective COX-2 inhibitor, was approved by the FDA for the treatment of the signs and symptoms of JIA in children aged 2-17…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].